Member Info for CHELSEA7

20/03/2019 14:56 8,102 5.96

Last 2 trades.......................

20/03/2019 14:21 86,843 5.9
20/03/2019 14:19 46,000 5.9

5.90 paid 12 times now, a decent size sell to come?? Volume 2.35m

20/03/2019 13:52 10,475 5.9
20/03/2019 12:57 50,000 5.9
20/03/2019 10:17 20,000 5.9
20/03/2019 09:34 5,000 5.52
20/03/2019 09:27 341,710 5.85
20/03/2019 08:32 5,000 5.505
20/03/2019 08:26 2,378 5.78

5.9P Paid 10 times now

On NEX....................

20/03/2019 12:57 50,000 5.9

Volume now 2.25m.....just MO more to come.

And Panmure join WINS on Bid at 5.6. Rarely in action..................but when they are!!!

20/03/2019 10:17 20,000 5.9
20/03/2019 09:34 5,000 5.52
20/03/2019 09:27 341,710 5.85
20/03/2019 08:32 5,000 5.505
20/03/2019 08:26 2,378 5.78

As seen from 09.27 at 5.85

From 10.26 at 5.60

2 More buys 40k and 50k, seconds apart at 5.90. Volume over 1.5m so far this morning.

Well a tick up on the bid.......it is 5.60/6

Two sells since 75k and 150k up to 5.75

One MM on bid still taking 75k at 5.62

Still seeing ii selling IMHO but very decent buying too up to 5.90

50k

From 8.03 at 5.78

""all """my recent buys shown as sells.

Anything i should know??, lol

Another 2 x 50k trades at 5.50..................volume 390k inside first hour.

SP still 5.5/6 UP 2.68%

A 90K trade at 5.50 just gone through, not so sure these trades are all sells at all.

MMs have increased from 30k to 35k what they will take at 5.505.

Volume so far 290k, 5 trades, showing as all sells, really???

Blue Sky:
At the turn of last year, Scancell reported “compelling” results from the Phase I/II melanoma trial of SCIB-1, and now it is waiting to kick off the Phase II clinical study of SCIB1 in combination with Keytruda later this year.

In December 2017, Cancer Research UK agreed to fund and sponsor a Phase I/II lung cancer clinical study of Scancell’s SCIB-2 vaccine, also in combination with a checkpoint inhibitor.

Lung cancer remains one of the most difficult cancers to treat and accounts for more than a quarter of all cancer deaths.

That is more than breast, prostate and colon cancers combined. Around 228,000 people receive a lung cancer diagnosis in the US alone and more than 160,000 will not survive.

In May 2018, investors got behind the business, backing a placing and subscription and open offer of new shares that brought in £8.7mln before expenses.

Those shares were sold at 12p each, but since then, the stock has drifted steadily back, currently trading at 6.30p, valuing Scancell at £25.79mln.

News on the start of the Phase II clinical study of SCIB1 in combination with Keytruda could see it return to the £50mln valuation of the May 2018 placing price.

All sells, 87k, 3k,50k and 50k at 5.50

Not ramping either, lol.

Probably the highest concentration of smokers in that area too. I have lived in both.

Just an 87k sell at 5.50, MMs remain unchanged

Will take 30k at 5.505 unchanged

5.50/6 +2.68%